[68Ga]Ga-PSMA-11 PET/MR-imaging of malignant intra-axial brain tumors; primary assessment of PSMA expression, optimization of compound delivery and determination of theranostic potential. - [68Ga]Ga-PSMA-11 PET/MR-imaging of malignant intra-axial brain tumors.

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•- Impaired renal function: eGFR (MDRD) <30 ml/min/1,73 m2
•- Impaired liver function: AST and ALT >= 2.5 x ULN
•- Karnofsky Performance score of less than 70
•- Previous other malignancies, except for any previous malignancy which was
•treated with curative intent more than 3 years prior to enrollment, and except
•for adequately controlled limited basal cell carcinoma of the skin, squamous
•carcinoma of the skin or carcinoma in situ of the cervix
•- Known history of cerebrovascular disease (e.g. ischemic stroke, cerebral
•hemorrhage)
•- Severe claustrophobia prohibiting PET/MRI scanning
•- A neurologic or psychiatric condition impairing judgement, making adequate
•informed consent impossible
•- Any psychological, familial, sociological or geographical condition hampering
•participation
•- Contra-indications for PET imaging (pregnancy or lactation; known allergic
•reaction to therapeutic radiopharmaceuticals)
•- Contra-indications for MR imaging
•- Contra-indications for arterial catheterization

发起方